Portal de Periódicos da CAPES

Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium

2018; Oxford University Press; Volume: 20; Issue: 7 Linguagem: Inglês

10.1093/neuonc/noy020

1523-5866

Kenneth Aldape, Samirkumar B. Amin, David M. Ashley, Jill S. Barnholtz‐Sloan, Amanda Bates, Rameen Beroukhim, Christoph Bock, Daniel J. Brat, Elizabeth B. Claus, J Costello, John F. de Groot, Gaetano Finocchiaro, Pim J. French, Hui Gan, Brent Griffith, Christel Herold‐Mende, Craig Horbinski, Antonio Iavarone, Steven N. Kalkanis, Konstantina Karabatsou, Hoon Kim, Mathilde C.M. Kouwenhoven, Kerrie L. McDonald, Hrvoje Miletić, Do‐Hyun Nam, Ho‐Keung Ng, Simone P. Niclou, Houtan Noushmehr, D. Ryan Ormond, Laila Poisson, Guido Reifenberger, Federico Roncaroli, K. Jason, Peter A.E. Sillevis Smitt, Marion Smits, Camila Ferreira de Souza, Ghazaleh Tabatabai, Erwin G. Van Meir, Roel G.W. Verhaak, Colin Watts, Pieter Wesseling, Adelheid Wöehrer, W.K. Alfred Yung, Christine Jungk, Ann‐Christin Hau, Eric Van Dyck, Bart A. Westerman, Julia Yin, Olajide Abiola, Nikolajs Zeps, Sean M. Grimmond, Michael E. Buckland, Mustafa Khasraw, Erik P. Sulman, Andrea Muscat, Lucy F. Stead,

Epigenetics and DNA Methylation

Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their families. The Cancer Genome Atlas and similar projects have provided a comprehensive understanding of the somatic alterations and molecular subtypes of glioma at diagnosis. However, gliomas undergo significant cellular and molecular evolution during disease progression. We review the current knowledge on the genomic and epigenetic abnormalities in primary tumors and after disease recurrence, highlight the gaps in the literature, and elaborate on the need for a new multi-institutional effort to bridge these knowledge gaps and how the Glioma Longitudinal Analysis Consortium (GLASS) aims to systemically catalog the longitudinal changes in gliomas. The GLASS initiative will provide essential insights into the evolution of glioma toward a lethal phenotype, with the potential to reveal targetable vulnerabilities and, ultimately, improved outcomes for a patient population in need.